Acceleron Pharma

Investors/Media

Press Releases

Date Title and Summary View
Toggle Summary Acceleron to Webcast Third Quarter 2017 Financial Results on November 7, 2017
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN) today announced it will host a webcast and conference call on Tuesday, November 7, 2017 at 8:00 a.m. EST to discuss its third quarter 2017 financial results and provide an update on recent clinical development and corporate
View HTML
Toggle Summary Acceleron Announces Closing of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare diseases, today announced that it has issued 810,810 shares of common stock at the public offering price
View HTML
Toggle Summary Acceleron Announces Pricing of Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics intended to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it has priced an
View HTML
Toggle Summary Acceleron Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and rare hematologic, neuromuscular, and pulmonary diseases, today announced that it intends to offer and sell,
View HTML
Toggle Summary Acceleron Showcases Vision and Strategy at 2017 R&D Day
- Clinical development and research efforts focused on hematological, neuromuscular and pulmonary diseases - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta therapeutics to treat serious and
View HTML
Toggle Summary Acceleron to Develop Sotatercept in Pulmonary Arterial Hypertension
- Acceleron gains rights to fund, develop, and lead global commercialization of sotatercept in pulmonary arterial hypertension - - Acceleron expects to initiate a Phase 2 trial of sotatercept in pulmonary arterial hypertension in 1H 2018 - - Preclinical results show potential first-in-class disease
View HTML
Toggle Summary Acceleron to Host Research and Development Day on September 19, 2017
- Acceleron's senior management team and external experts to present clinical development programs and preclinical research efforts - - Live conference call and webcast scheduled for 8:00 a.m. EDT on September 19 th - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc.
View HTML
Toggle Summary Acceleron Announces Publication of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results in The Lancet Oncology
CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ: XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to treat serious and rare diseases, announced that The Lancet Oncology has published results
View HTML
Toggle Summary Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results
- Completed full enrollment of luspatercept MEDALIST and BELIEVE Phase 3 trials - - Presented updated luspatercept Phase 2 results in patients with MDS and beta-thalassemia receiving treatment for up to two years - - Treated first patient in ACE-083 Phase 2 study in Charcot-Marie-Tooth disease - -
View HTML
Toggle Summary Acceleron Announces First Patient Treated in Phase 2 Clinical Trial of ACE-083 in Charcot-Marie-Tooth Disease
- Phase 2 trial in CMT expands wholly-owned ACE-083 program and muscle franchise into new area of high unmet medical need - CAMBRIDGE, Mass. --(BUSINESS WIRE)-- Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery, development and
View HTML